All In Biotech

Drug Trial Radar · NCT06789861

A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients

A First in Human, Three-part, Double Blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate Safety and Pharmacokinetics of TT5 in Healthy Participants and Surgical Patients

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

May 23, 2025

Primary completion

Oct 1, 2026

Study completion Nov 10, 2026

Sponsor

Lead sponsor
Tafalgie TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a First in Human, three-parts, double-blind, randomized, placebo-controlled, single and multiple ascending dose study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT5 at different doses in healthy and surgical participants.

Conditions

  • Pain

Interventions

  • TT5Drug

    Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients

  • Placebo - TT5 vehicleDrug

    Intravenous administration of vehicule, according to the same drug regimen than TT5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and serious adverse events (SAEs)Time frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
  2. Clinically significant changes in physical examinationsTime frame: SAD cohorts: Baseline through Day 8; MAD cohorts: Baseline through Day 14
  3. Clinically significant changes in vital signsTime frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
  4. Clinically significant changes in laboratory analysisTime frame: SAD cohorts: Day-1 through Day 8; MAD cohorts: Day-1 through Day 14
  5. Bond and Lader Visual Analog Scale (VAS)Time frame: SAD cohorts: Day 1 through Day 8; MAD cohorts: Day 1 through Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cmax & PARC

    Adelaide, South Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.